bioRxivImmunologyPreprint
A class act: HDAC1-Malat1 regulates MDSC apoptosis and cell cycling to decrease suppression of T cells
Aaron G. BaughiD, Yingtong LiuiD, Edgar Gonzalez, Batul Al-ZubeidyiD, Mukund Iyer, Alex LeeiD, Nana Gyabaah-Kessie, Matthew B. JacoboiD, Cheol H. ParkiD, Jesse KregeriD, Lori Khatchaturian, Sabrina K. Zhong, Kaliya Acevedo, Saul J. PricemaniD, Josh NemaniD, Adam L. MacLeaniD, Evanthia T. Roussos TorresiD
- Citations
- 2
Abstract
Myeloid derived suppressor cells (MDSCs) are key players in the immune-suppressed tumor microenvironment (TME) and significantly contribute to immune checkpoint inhibition (ICI) resistance, making them favorable targets for cancer immunotherapy. Epigenetic reprogramming of MDSCs using histone deacetylase (HDAC) inhibitors shows promise to sensitize the TME to ICIs. However, the molecular mechanism of HDAC inhibition in MDSCs has yet to be elucidated. Murine and human MDSC models treated with Entinostat revealed that the long non-coding RNA Malat1 downregulates pSTAT3 and decreases MDSC-mediated suppression of T cell proliferation. Through HDAC inhibitor screens, we identified HDAC1 as preferentially regulating Malat1 expression, STAT3 activation, and MDSC suppression. We also show that HDAC1 inhibition increases MDSC apoptosis by shifting pro-vs. anti-apoptotic signals and increases G0/G1 cell cycle arrest via decreasing G1-S transition cyclin-CDK complexes. Collectively, our findings provide a multi-pronged mechanism of HDAC inhibition in MDSCs that inform the development of future rational combination therapies. One Sentence SummaryHDAC1 inhibition in MDSCs increases Malat1, decreases pSTAT3, induces apoptosis/cell cycle arrest, and decreases suppression of T cells
- organism: human
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- HDAC1-3 inhibition reduces CCR2 expression and immunosuppressive function of myeloid-derived suppressor cells
Z. Xie, Y. Okada, … M. Tachibana·bioRxiv·Jun 1, 2023
- Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells
Julian Schliehe‐Diecks, Jia‐Wey Tu, … Sanil Bhatia·Cell Death and DiseasePeer-reviewed·Mar 7, 2026
- Phenotypic shifts of tumor associated macrophages and STAT3 mediated suppression of myeloid derived suppressor cells drive sensitization of HER2+ tumor immunity.
D. N. Sidiropoulos, C. Rafie, … E. T. Roussos-Torres·bioRxiv·Jan 29, 2021
- Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit
J. Salmon, I. Todorovski, … R. W. Johnstone·bioRxiv·Aug 23, 2020
- HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy
Maša Zrimšek, Kristina Draganić, … Gerda Egger·LeukemiaPeer-reviewed·Apr 2, 2025
- HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells
C. Yerinde, J. Keye, … C. Weidinger·bioRxiv·Sep 18, 2022